

#4

Sheet 1 of 4

INSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR §1.98(b))	Attorney Docket No.	50036/021004
	Serial No.	09/688,566
	Applicant	Dasa Lipovsek et al.
	Filing Date	October 16, 2000
	Group	
	IDS Filed	November 6, 2000

113
09/515,268

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
HA	6,018,030	01/25/00	Ferrari et al.			
HA	5,792,742	08/11/98	Gold et al.			
HA	5,770,697	06/23/98	Ferrari et al.			
HA	5,641,648	06/24/97	Ferrari et al.			
HA	5,545,620	08/13/96	Wahl et al.			
HA	5,514,581	05/07/96	Ferrari et al.			
HA	5,235,041	08/10/93	Cappello et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
HA	WO 00/34784	06/15/00	PCT			
HA	WO 98/56915	12/17/98	PCT			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)


HA	Baron et al., "H NMR Assignment and Secondary Structure of the Cell Adhesion Type III Module of Fibronectin," <i>Biochemistry</i> 31:2068-2073 (1992).
HA	Boder et al., "Yeast Surface Display for Screening Combinatorial Polypeptide Libraries," <i>Nature Biotechnology</i> 15:553-557 (1997).
HA	Bork and Doolittle, "Proposed Acquisition of an Animal Protein Domain by Bacteria," <i>Proc. Natl. Acad. Sci. USA</i> 89:8990-8994 (1992).
HA	Campbell et al., "Building Proteins with Fibronectin Type III Modules," <i>Structure</i> 2:333-337 (1994).
HA	Clackson and Wells, "In-Vitro-Selection-from-Protein-and-Peptide-Libraries," <i>TIBTECH</i> 12:173-184 (1994).
HA	Clackson et al., "Making Antibody Fragments Using Phage Display Libraries," <i>Nature</i> 352:624-628 (1991).

EXAMINER

DATE CONSIDERED

5/25/03

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 CFR §1.98(b))

Attorney Docket No.

50036/021004

Serial No.

09/688,566

Applicant

Dasa Lipovsek et al.

Filing Date

October 16, 2000

Group

IDS Filed

November 6, 2000

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)


HA	Clarke et al., "Folding and Stability of a Fibronectin Type III Domain of Human Tenascin," <i>J. Mol. Biol.</i> 270:771-778 (1997).
HA	Copie et al., "Solution Structure and Dynamics of Linked Cell Attachment Modules of Mouse Fibronectin Containing the RGD and Synergy Regions: Comparison with the Human Fibronectin Crystal Structure," <i>J. Mol. Biol.</i> 277:663-682 (1998).
HA	Dickinson et al., "Crystals of the Cell-Binding Module of Fibronectin Obtained From a Series of Recombinant Fragments Differing in Length," <i>J. Mol. Biol.</i> 238:123-127 (1994).
HA	Dickinson et al., "Crystal Structure of the Tenth Type III Cell Adhesion Module of Human Fibronectin," <i>J. Mol. Biol.</i> 236:1079-1092 (1994).
HA	Ely et al., "Common Molecular Scaffold for Two Unrelated RGD Molecules," <i>Protein Eng</i> 8:823-827 (1995).
HA	Ghosh et al., "Structure of NF-kB p50 Homodimer Bound to a kB Site," <i>Nature</i> 373:303-310 (1995).
HA	Grant et al., "Structural Requirements for Biological Activity of the Ninth and Tenth FIII Domains of Human Fibronectin," <i>J. Biol. Chem.</i> 272:6159-6166 (1997).
HA	Hamers-Gasterman et al., "Naturally Occurring Antibodies Devoid of Light Chains," <i>Nature</i> 363:446-448 (1993).
HA	Hocking et al., "A Novel Role for the Integrin-Binding III-10 Module in Fibronectin Matrix Assembly," <i>The Journal of Cell Biology</i> 133:431-444 (1996).
HA	Hocking et al., "Activation of Distinct $\alpha_5\beta_1$ -Mediated Signaling Pathways by Fibronectin's Cell Adhesion and Matrix Assembly Domains," <i>The Journal of Cell Biology</i> 141:241-253 (1998).
HA	Hynes, "Integrins: Versatility, Modulation, and Signaling in Cell Adhesion," <i>Cell</i> 69:11-25 (1992).
HA	Kohler and Milstein, "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," <i>Nature</i> 256:495-497 (1975).
HA	Koide et al., "Directed Evolution of Fibronectin Type III Domain to Novel Ligand Binding Proteins," <i>Combinatorial Approaches Abstract M40</i>
HA	Koide et al., "The Fibronectin Type III Domain as a Scaffold for Novel Binding Proteins," <i>J. Mol. Biol.</i> 284:1141-1151 (1998).

EXAMINER

DATE CONSIDERED

5/25/03

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this



SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 CFR §1.98(b))

Attorney Docket No.	50036/021004
Serial No.	09/688,566
Applicant	Dasa Lipovsek et al.
Filing Date	October 16, 2000
Group	
IDS Filed	November 6, 2000

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

1	Koide et al. "Directed Evolution of Fibronectin Type III Domain to Novel Ligand Binding Proteins," <i>Designing Small and Large Molecules I</i> Abstract 1739
2	Ku and Schultz, "Alternate Protein Frameworks for Molecular Recognition," <i>Proc. Natl. Acad. Sci. USA</i> 92:6552-6556 (1995).
3	Leahy et al., "Structure of a Fibronectin Type III Domain from Tenascin Phased by MAD Analysis of the Selenomethionyl Protein," <i>Science</i> 258:987-991 (1992).
4	Litvinovich and Ingham, "Interactions Between Type III Domains in the 110 kDa Cell-Binding Fragment of Fibronectin," <i>J. Mol. Biol.</i> 248:611-626 (1995).
5	Lombardo et al., "Conformational Flexibility and Crystallization of Tandemly Linked Type III Modules of Human Fibronectin," <i>Protein Sci</i> 5:1934-1938 (1996).
6	Main et al., "The Three-Dimensional Structure of the Tenth Type III Module of Fibronectin: An Insight into RGD-Mediated Interactions," <i>Cell</i> 71:671-678 (1992).
7	Markland et al., "Iterative Optimization of High-Affinity Protease Inhibitors Using Phage Display. 1. Plasmin," <i>Biochemistry</i> 35:8045-8057 (1996).
8	Markland et al., "Iterative Optimization of High-Affinity Protease Inhibitors Using Phage Display. 2. Plasma Kallikrein and Thrombin," <i>Biochemistry</i> 35:8058-8067 (1996).
9	McConnell and Hoess, "Tendamistat as a Scaffold for Conformationally Constrained Phage Peptide Libraries," <i>J. Mol. Biol.</i> 250:460-470 (1995).
10	Meinke et al., "Cellulose-Binding Polypeptides from <i>Cellulomonas fimi</i> : Endoglucanase D (CenD), a Family A β -1,4-Glucanase," <i>J. Bacteriology</i> 175:1910-1918 (1993).
11	Muller et al., "Structure of the NF-kB p50 Homodimer Bound to DNA," <i>Nature</i> 373:311-317 (1995).
12	Nord et al., "Binding Proteins Selected From Combinatorial Libraries of an α-Helical Bacterial Receptor Domain," <i>Nature Biotechnology</i> 15:772-777 (1997).
13	Nord et al., "A Combinatorial Library of an α -Helical Bacterial Receptor Domain," <i>Protein Eng.</i> 8:601-608 (1995).
14	Nygren and Uhlen, "Scaffolds for Engineering Novel Binding Sites in Proteins," <i>Current Opinion in Structural Biology</i> 7:463-469 (1997).
15	Plaxco et al., "Rapid Refolding of a Proline-Rich All- β -Sheet Fibronectin Type III Module," <i>Proc. Natl. Acad. Sci. USA</i> 93:10703-10706 (1996).
16	Plaxco et al., "A Comparison of the Folding Kinetics and Thermodynamics of Two Homologous Fibronectin Type III Modules," <i>J. Mol. Biol.</i> 270:763-770 (1997).
17	Potts and Campbell, "Structure and Function of Fibronectin Modules," <i>Matrix Biology</i> 15:313-320 (1996).
18	Potts and Campbell, "Fibronectin Structure and Assembly," <i>Curr. Opin. Cell Biol.</i> 6:648-655 (1994).

EXAMINER

DATE CONSIDERED

5/25/03

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Attorney Docket No.

50036/021004

Serial No.

09/688,566

Applicant

Dasa Lipovsek et al.

Filing Date

October 16, 2000

Group

IDS Filed

November 6, 2000

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

CFR §1.98(b))



OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

_____	Roberts and Szostak, "RNA-Peptide-Fusions-for-the-In-Vitro-Selection-of-Peptides-and-Proteins," <i>Proc. Natl. Acad. Sci. USA</i> 94:12297-12302 (1997).
HA	Rottgen and Collins, "A Human Pancreatic Secretory Trypsin Inhibitor Presenting a Hypervariable Highly Constrained Epitope Via Monovalent Phagemid Display," <i>Gene</i> 164:243-250 (1995).
HA	Shibata et al., "An Attempt to Substitute the Cell Binding Domain of Human Fibronectin in Lambda Phage J Protein: Computer Design and Expression," <i>Biochimie</i> 75:459-465 (1993).
HA	Smith and Petrenko, "Phage Display," <i>Chem. Rev.</i> 97:391-410 (1997).
HA	Tramontano et al., "The Making of the Minibody: An Engineered β -Protein for the Display of Conformationally Constrained Peptides," <i>J. Molecular Recognition</i> 7:9-24 (1994).
HA	Wang et al., "Isolation of a High Affinity Inhibitor of Urokinase-Type Plasminogen Activator by Phage Display of Ecotin," <i>J. Biol. Chem.</i> 270:12250-12256 (1995).
HA	Watanabe et al., "Gene Cloning of Chitinase A1 From <i>Bacillus Circulans</i> WL-12 Revealed Its Evolutionary Relationship to Serratia Chitinase and to the Type III Homology Units of Fibronectin," <i>J. Biol. Chem.</i> 265:15659-15665 (1990).
HA	Williams et al., "Solution Structures of Modular Proteins by Nuclear Magnetic Resonance," <i>Methods Enzymol</i> 245:451-469 (1994).
HA	Williams and Barclay, "The Immunoglobulin Superfamily - Domains for Cell Surface Recognition," <i>Ann. Rev. Immunol.</i> 6:381-405 (1988).
EXAMINER	DATE CONSIDERED
<i>[Signature]</i>	5/25/03
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



#9

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50036/021004		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR §1.98(b))		Serial No.		09/688,566		
		Applicant		Dasa Lipovsek et al.		
		Filing Date		October 16, 2000		
		Group		1653		
		IDS Filed		May 13, 2002		
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
<i>[Signature]</i>	WO 02/04523 A2	01/17/02	PCT			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
EXAMINER	<i>[Signature]</i>			DATE CONSIDERED		
				5/22/03		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

TECH CENTER 1600/2900

MAY 21 2002


RECEIVED

#5
 RECEIVED
 SEP 13 2001

TECH CENTER 1600/2900

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50036/021004 Serial No. 09/688,566 Applicant Dasa Lipovsek et al. Filing Date October 16, 2000 Group 1645 IDS Filed September 6, 2001				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)						
(37 CFR §1.98(b))						
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
<i>[Signature]</i>	WO 98/31700	7/23/98	PCT			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
EXAMINER <i>[Signature]</i>				DATE CONSIDERED 5/22/03		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						





COPY OF PAPERS
ORIGINALLY FILED

Sheet 1 of 1

#7

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.		50036/021004	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. §1.98(b))				Serial No.		09/688,566	
				Applicant		Dasa Lipovsek et al.	
				Filing Date		October 16, 2000	
				Group		1645	
				IDS Filed		April 11, 2002	
U.S. PATENTS							
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)	
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)	
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)							
	Lee et al., "Strong Inhibition of Fibrogen Binding to Platelet Receptor Alpha2b beta3 by RGD Sequences Installed into a Presentation Scaffold," <i>Protein Engineering</i> 6:745-754 (1993).						
	Bianchi et al., "High Level Expression and Rational Mutagenesis of a Designed Protein, the Minibody," <i>J. Mol. Biol.</i> 236:649-659 (1994).						
EXAMINER				DATE CONSIDERED 5/22/03			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.							

RECEIVED
APR 24 2002
TECH CENTER 1600/2900



RECEIVED
OCT 28 2002
TECH CENTER 1600/2900

Sheet 1 of 1

#14

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed		50036/021004 09/688,566 Dasa Lipovsek et al. October 16, 2000 1653 October 21, 2002	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)							
(37 C.F.R. § 1.98(b))							
U.S. PATENTS							
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)	
<i>A</i>	6,462,189 B1	10/08/02	Koide				
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)	
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)							
EXAMINER	<i>[Signature]</i>			DATE CONSIDERED 5/22/03			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.							